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Pancreatic cancer is still a dismal disease. The high mortality rate is mainly caused by the lack of highly sensitive and specific
diagnostic tools, and most of the patients are diagnosed in an advanced and incurable stage. Knowledge about precursor lesions
for pancreatic cancer has grown significantly over the last decade, and nowadays we know that mainly three lesions (PanIN, and
IPMN, MCN) are responsible for the development of pancreatic cancer. The early detection of these lesions is still challenging but
provides the chance to cure patients before they might get an invasive pancreatic carcinoma. This paper focuses on PanIN, IPMN,
and MCN lesions and reviews the current level of knowledge and clinical measures.
1. Introduction
Pancreatic cancer is the fourth leading cause of cancer death
in the USA [1]. The high mortality rate is mainly caused by
the lack of highly sensitive and specific tools to detect the
disease in an early stage, and therefore most of the patients
are diagnosed in advanced tumor stages. Currently, surgical
resection is the only curative treatment option.However, only
a small number of patients (30–40%) presentwith a resectable
tumor at the time of diagnosis. The overall five-year survival
after pancreatic head resection for cancer has been reported
to range between 10 and 25% [2, 3]. The five-year survival
rate can be significantly improved for patients with pancreatic
cancer when surgery is possible and patients additionally
receive adjuvant therapy [4, 5]. However, there are patients
that relapse shortly after the surgery and, therefore, have
only a limited life span even after complete resection of the
tumor.
Current knowledge about pancreatic carcinogenesis pos-
tulates—analogous to other carcinomas—a stepwise progres-
sion from intraepithelial neoplasia to invasive cancer [6, 7].
Studies of resected pancreata from patients with a family his-
tory of pancreatic cancer or from patients with ductal
adenocarcinoma of the pancreas (PDAC) demonstrated
that many patients have multifocal, microscopic pancreatic
intraepithelial neoplasms (PanINs) surrounding the tumor
and in the remainder of the pancreas [8–11]. Furthermore,
cystic lesions of the pancreas like intraductal papillary muci-
nous neoplasms (IPMNs) or mucinous cystic neoplasms
(MCNs) are well known as precursor lesions for pancreatic
cancer (Figure 1) [12–15]. Early detection and treatment of
the abovementioned precursor lesions could probably save
patients from advancing to invasive pancreatic cancer. In this
review, a summary of the most important precursor lesions
for pancreatic cancer, that is, PanIN, IPMN, and MCN, is
given.
2. Pancreatic Intraepithelial
Neoplasia (PanIN)
The most important and well-known precursor of a PDAC
is pancreatic intraepithelial neoplasia (PanIN). For several
decades, this noninvasive ductal lesion was described using
multiple terminologies. Hruban et al. first presented the
nowadays generally accepted “PanIN scheme” to classify
these lesions in 2001 (Figure 2) [16, 17].
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Figure 1: Model of three distinct morphological pathways to invasive pancreatic carcinoma.
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Figure 2: Compendium of molecular changes during the PanIN-progression model. Adapted from [6, 18].
2.1. Histology. A PanIN is a microscopic (usually <5mm)
flat or papillary lesion arising in the small intralobular
pancreatic ducts [17]. These lesions are characteristically
asymptomatic. PanINs are composed of columnar to cuboidal
cells with varying amounts of mucin and varying degrees of
cytological and architectural atypia [15]. They are classified
into three grades: PanIN-1A (flat) and PanIN-1B (papillary)
are low-grade lesions with minimal cytological and architec-
tural atypia (Figure 3). PanIN-2 lesions (intermediate-grade
PanIN) show mild to moderate cytological and architectural
atypia (e.g., nuclear pleomorphism, nuclear crowding, and
nuclear hyperchromasia) with frequent papillae (Figure 4)
[6, 15]. High-grade PanINs (PanIN-3) are characterized by
severe cytological and architectural atypia. PanIN-3 is also
referred to as “carcinoma in situ.” All PanINs are noninvasive
lesions that do not trespass the basement membrane [16, 17].
PanIN-3 lesions usually have a papillary morphology but
can also present with a flat or cribriform pattern (Figure 4).
In addition, there are some rare variants of PanINs (e.g.,
intestinal type, foam gland type, and oncocytic type) that do
not seem to have any specific clinical significance [15].
Formal pancreatic carcinogenesis is thought to progress
from low-grade to high-grade PanIN and then to invasive
cancer; this histological progression is paralleled by the
accumulation of genetic changes (Figure 2).
2.2. Immunohistochemical Characteristics. The immunohis-
tochemical characteristics of PanINs vary with the grade of
dysplasia. In particular, the apomucins MUC1, MUC2, and
MUC5AC are frequently overexpressed in epithelial cancers
of the gastrointestinal tract [14, 19]. MUC1 is responsible for
the surveillance of lumen formation and is typically expressed
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Figure 3: (a) PanIN 1A lesion with flat epithelium, basal nuclei, and abundant supranuclear mucin. (b) PanIN 1A and 1B (arrow) lesion with
papillary architecture and slight nuclear atypia (H&E ×20).
(a) (b)
Figure 4: (a) PanIN-2 lesion with moderate cytological atypia, retained nuclear polarity, and partially papillary architecture (H&E, 20x); (b)
PanIN-3 lesion with severe cytological atypia, lost nuclear polarity, and papillary architecture (H&E, 40x).
by the pancreatic ducts and centroacinar cells. Furthermore,
MUC1 is almost exclusively expressed in the higher-graded
lesions (PanIN-2/PanIN-3) and often linked with an invasive
PDAC [18, 20]. The intestinal mucin marker MUC2 and
the intestinal differentiation marker CDX-2 are negative in
common-type PanIN andPDAC.However,MUC2 andCDX-
2 expression is seen in IPMNs with intestinal differentiation
and therefore can be used for differentiation between PanINs
and intestinal IPMNs [14, 19, 21]. In contrast to MUC1,
MUC5AC is not expressed by the normal pancreatic ducts
but, similar to MUC1, in the majority of invasive ductal
carcinomas and moreover already in the early PanIN lesions
[6, 18, 20, 22, 23]. Furthermore, the membrane-associated
mucins MUC3 and MUC4 show a progressive increase in
PanIN lesions of increasing dysplasia and are also highly
expressed in ductal adenocarcinoma [20, 24, 25].
2.3. Genetic and Epigenetic Changes. As mentioned above,
PanINs are part of the multistep tumor progression model
in pancreatic cancer. Early genetic alterations include telom-
erase shortening, V-Ki-ras2 Kirsten rat sarcoma viral onco-
gene homolog (KRAS) activation, and inactivation of tumor
suppressor genes cyclin-dependent kinase inhibitor p16
(p16)/cyclin-dependent kinase inhibitor 2A (CDKN2A) [17].
KRAS mutations are one of the earliest genetic abnormalities
in the progressionmodel for pancreatic cancer [26].Themost
common activating point mutations are located in codons 12
and 13 of exon 2 of the KRAS gene (in over 90% of PDACs)
[6, 27, 28]. Early KRAS mutation is thought to be the driver
for the formation of pancreatic cancer [29].
Telomere shortening is another early event in the progres-
sion model of pancreatic cancer. Telomeres are structures at
the end of the chromosomes with a protective effect. They
prevent fusion between the ends of the chromosomes. Telom-
eres shorten with the age of the cell and the number of cell
divisions. Shortened telomeres lead to an abnormal fusion
of chromosomes with chromosome instability, promoting
neoplastic progression in the cells [6, 30].
In addition to activating KRAS mutations, leading to
increased proliferation, and telomere shortening, leading
to chromosomal instability, the inactivation of three tumor
suppressor genes (p16/CDKN2A, tumor protein 53 (TP53),
and SMAD familymember 4 (SMAD4/DPC4)) is relevant for
the formation of pancreatic cancer. While the inactivation of
p16/CDKN2A is already detectable in the early PanIN stages,
the inactivation of TP53 and SMAD4/DPC4 is associated
with later alterations in the tumor progression model [17].
The p16/CDKN2A gene is located on the short arm of
chromosome 9, and almost all pancreatic carcinomas present
a loss of the p16/CDKN2A function [31]. Inactivation of p16
leads to an inadequate progression through the G1 phase of
the cell cycle.
The TP53 tumor suppressor gene encodes for the p53
protein that is involved in the regulation of the cell cycle,
maintenance of the G2/M arrest, and the induction of
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apoptosis. Loss of p53 causes deregulation in cell death and
cell division [18, 32].
The gene DPC4 (located on chromosome 18q) encodes
for the SMAD4 protein that plays an important role in
signaling through the transforming growth factor type 𝛽
(TGF-𝛽) pathway. SMAD4 has a growth-controlling effect by
regulating the expression of specific genes [33, 34].Therefore,
loss of SMAD4 leads to a decreased growth inhibition and
thereby supports the growth of cancer cells.
Epigenetic changes predominantly occur throughmethy-
lation of CpG islands, which are located in the promoter
regions of genes leading to gene silencing [35]. Numerous
studies have demonstrated hypermethylation of several genes
in patientswith pancreatic cancer [36, 37]. Amicroarray anal-
ysis by Sato et al. showed that aberrant CpG island hyperme-
thylation begins in early stages of PanINs, and its prevalence
progressively increases during neoplastic progression [38].
Furthermore, the detection of aberrantlymethylated genes by
methylation-specific PCR in the pancreatic juice might be an
interesting diagnostic tool for the future [39].
2.4. Clinical Relevance of PanIN. Asmentioned above, PanIN
lesions are precursor lesions in the stepwise progression
from intraepithelial to invasive pancreatic neoplasia. This
morphological progression is paralleled by an accumulation
of genetic changes in which activating KRAS mutations are
thought to be the driving force (Figure 2). Early detection of
PanINs would present an opportunity to cure patients before
they develop invasive pancreatic cancer, but unfortunately
PanINs are not yet detectable by cross-sectional imaging
or endoscopic ultrasound (EUS). Molecular markers in the
pancreatic juice may help to solve this dilemma. The most
appropriate approach to the pancreatic resection margin
when it harbors a PanIN lesion (detected by intraoperative
frozen section) is, however, not clear. In particular, no
consensus has been achieved on how to handle PanIN-3
lesions in the resection margin [40]. We would recommend
an additional resection in cases with PanIN-3 lesions (in the
resectionmargin), whereas an additional resection in PanIN-
1 and -2 lesions might not be necessary.
3. Intraductal Papillary Mucinous
Neoplasm (IPMN)
IPMNs belong to the heterogeneous group of cystic pancre-
atic lesions with increasing incidence in recent years [41–43].
These cystic lesions were initially reported in the 1990s, and
the term IPMN was established in the 2000 classification of
the WHO [44]. IPMNs are tumors of the duct epithelium.
Papillary epithelial proliferation and mucin production lead
to cystic dilatation of involved ducts [43]. IPMNs have
been proven to be invasive carcinoma precursors, and thus
progression models from noninvasive intraductal tumors via
borderline lesions to invasive carcinoma have been developed
(Figure 1) [45–47].
3.1. Histology and Immunohistochemistry. Morphologically,
IPMNs are subdivided into the main (MD-IPMN) and
branch duct types (BD-IPMN) according to their site of
Table 1: Subtype classification of IPMN by immunohistochemical
analysis and arising invasive carcinoma [48–50].
IPMN (subtype) Expression profile Invasive carcinoma
Intestinal
(MD-IPMN)
MUC5AC+, MUC2+,
CDX-2+
(MUC1−, MUC6−)
Colloidal
carcinoma
Pancreatobiliary
(MD-IPMN)
MUC5AC+,MUC1+
(MUC2−, MUC6+/−)
Tubular (ductal)
carcinoma
Gastric
(BD-IPMN)
MUC5AC+, (MUC6+)
(MUC1−, MUC2−)
Tubular (ductal)
carcinoma
Oncocytic
(MD-IPMN)
MUC5AC+,MUC6+
(MUC2+/−) (MUC1+/−)
Oncocytic
carcinoma
origin. When the main and branch ducts are both involved,
the terms “mixed duct type” and “combined duct type” are
used [51, 52]. Due to the papillary epithelial proliferation and
mucin production, MD-IPMNs typically show a dilatation
of the main pancreatic duct >6mm. BD-IPMNs show no
dilatation of the main pancreatic duct but a communi-
cation of the cystic lesion with the main duct, typically
well definable by MRI/MRCP imaging. Some IPMNs might
be multifocal and therefore even after partial pancreatic
resection there is a risk of progression of a synchronous
cystic lesion [53, 54]. Depending on their degree of dyspla-
sia and the presence or absence of an associated invasive
carcinoma, IPMNs are subclassified by the WHO into low-
grade dysplasia, intermediate-grade dysplasia, high-grade
dysplasia, and IPMN with associated invasive carcinoma
[55]. Approximately, one-third of patients with IPMN are
associated with invasive carcinoma [12, 14, 51, 56]. On the
basis of their histological and immunohistochemical char-
acteristics, intestinal, pancreatobiliary, oncocytic, and gastric
subtypes of IPMN are distinguishable [14, 57]. Differential
diagnosis of histopathological subtypes is accomplished by
histomorphological and immunohistochemical analysis of
MUC expression (MUC1, MUC2, MUC5AC, and MUC6)
and the intestinal marker CDX-2 (Table 1) [19, 57, 58].
Intestinal-type IPMN is characterized by tall colum-
nar cells with elongated nuclei and amphophilic cytoplasm
(similar to villous adenoma of the colorectum). The lesions
frequently exhibit moderate or severe dysplasia [15]. These
villous papillary neoplasms typically show an expression of
MUC2, MUC5AC, and CDX-2 (Figure 5) (Table 1). A recent
article byKitazono et al. also demonstratedMUC4 expression
in IPMN and especially in intestinal-type IPMN [59].
In contrast, the pancreatobiliary subtype of IPMN is
characterized by branched papillae with high-grade intraep-
ithelial neoplasms. The pancreatobiliary subtype is usually
associated with an invasive component/IPMN-associated
carcinoma. Immunohistochemical staining shows expression
of MUC1 and MUC5AC (Figure 5) (Table 1) [60]. The third
and rare subtype of MD-IPMN is the oncocytic type. This
subtype mainly presents with oncocytic cells with a complex
branched papillary structure and an eosinophilic cytoplasm
(with intracytoplasmic lumina) mixed with goblet cells and
mucin-containing cells [15]. Most of these cells show high-
grade cellular atypia and carcinoma in situ modifications
BioMed Research International 5
(a) (b)
(c) (d)
(e) (f)
Figure 5: (a) and (b) IPMN gastric foveolar (branch duct) subtype with low-grade dysplasia, partially flat, partially papillary architecture,
and basally oriented nuclei ((a); H&E 20x, (b); MUC5AC 20x); (c) and (d) IPMN intestinal subtype with low/intermediate dysplasia, long,
finger-like papillae, and elongated nuclei ((c); H&E 4x, (b); MUC2 10x); (e) and (f) IPMNpancreatobiliary subtype with high-grade dysplasia,
lost nuclear orientation, and complex papillae formation ((e); H&E 20x, (f); MUC1 20x).
and convert into the infrequent oncocytic carcinoma when
they become invasive. The oncocytic subtype is immuno-
histochemically characterized by a diffuse positivity for
MUC5AC, MUC6, and a focal positivity for MUC1 or MUC
2 (Table 1). The gastric subtype, mainly found in BD-IPMN,
is characterized by a foveolar glandular epithelium (similar
to gastric foveolar cells) with formation of papillae. The
cells present with oval-shaped nuclei with mild atypia and a
slightly eosinophilic cytoplasm. Mitoses are rare, and most
of the gastric-type lesions are low-grade lesions. Gastric-type
IPMNs express MUC5AC and sometimes MUC6 (Table 1)
[48, 49, 61].
While intestinal, pancreatobiliary, and oncocytic sub-
types primarily originate in the main duct, the gastric
subtype is typically derived from branch ducts.When IPMNs
become invasive, two distinct types of invasive carcinomas
typically develop, that is, tubular and colloid (mucinous
noncystic) carcinomas (Table 1) [14, 45, 62]. While colloid
carcinomas (characterized by abundant extracellular pools of
mucin with floating neoplastic epithelium) usually arise from
intestinal-type IPMNs, thetubular adenocarcinoma mainly
arising from pancreatobiliary-type IPMN (invasive IPMN)
and PDAC are morphologically similar, but they may not
be the same. For instance, tubular-type invasive IPMN may
harbor GNAS mutations. The distinction of these two tumor
types has prognostic relevance because patients with colloid
carcinomas have a better five-year survival rate than patients
with tubular carcinomas [14, 48, 63, 64]. Other factors
determining the prognosis of patients with IPMN are the
presence of an invasive carcinoma, the lymph node ratio, and
the histopathological subtype [56, 65, 66].
3.2. Molecular Pathology and Genetic Changes. Studies have
identified a wide variety of genetic changes in IPMNs
and some of them are similar to the findings in PDAC
including KRAS, p16/CDKN2A, SMAD4, and TP53 genes
[55, 67]. Other mutations, such as phosphatidylinositol-4,5-
bisphosphate 3-kinase (PIK3CA) and v-Raf murine sarcoma
viral oncogene homolog B1 gene (BRAF) mutations, are
found in a small fraction of IPMNs [68, 69]. Recent studies by
Wu et al. and Furukawa et al. added important information
about the molecular anomalies of IPMN [70, 71]. They found
that >96% of IPMNs have either a GNAS complex locus
(GNAS) or a KRAS mutation and more than half of them
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Table 2: Core characteristics of cystic lesions of the pancreas (adapted from [47]).
IPMN SCN MCN SPN Pseudocysts
Mean age (years) 60–70 70 40–50 30 30–50
Sex 60–70%male
90%
female
>95%
female
90%
female
70–80%
male
Localization
(average) Pancreatic head Pancreatic tail Pancreatic body and tail
Pancreatic body and
tail Pancreas ubiquitary
Imaging and MPD
Segmental or diffuse
enlargement of the
MPD and obligatory
communication to the
MPD
Microcystic lesion
with central scar and
calcification (or
macrocystic lesion
without central scar
possible); no
connection to the
MPD
Macrocystic lesion with
septation and calcification
of the wall; no connection
to the MPD
Mixed solid cystic
lesion; no connection
to the MPD
Macrocystic lesion
without septation;
connection to the
MPD and probably
signs of pancreatitis;
enlargement of MPD
possible
CEA in cyst High Low High Low Low
Mucin production Yes No Yes No No
Amylase in cyst High Low Low Low High
MPD:main pancreatic duct; CEA: carcinoembryonic antigen; IPMN: intraductal papillarymucinous neoplasm; SCN: serous cystic neoplasm;MCN:mucinous
cystic neoplasm; SPN: solid pseudopapillary neoplasm.
have bothmutations.The results of these studies indicate that
GNAS mutations are common and specific for IPMN, and
activation of G-protein signaling appears to play a pivotal
role in IPMN. Although these mutations were found in all
IPMN subtypes, GNAS mutations were more prevalent in
the intestinal subtype, whereas KRAS mutations were more
prevalent in the pancreatobiliary subtype [70–72]. Only a
little is known about the characteristics of the oncocytic
subtype of IPMN. KRASmutations and TP53 overexpression
are less frequently identified in oncocytic-type IPMN than
in pancreatobiliary-type IPMN (17% and 11% versus 58% and
58%, resp.). However, the less frequent TP53 overexpression
in the oncocytic subtype, associated with significantly lower
rates of invasion and nodal involvement, correlates with a
better outcome compared to pancreatobiliary-type IPMN
[14, 73].
Current studies have evaluated the identification of mo-
lecularmarkers in the pancreatic juice. Siddiqui et al. demon-
strated that the presence of GNAS in combination withKRAS
mutations in pancreatic cystic fluid obtained by EUS-FNA
improves the sensitivity for diagnosis of IPMN (accuracy
80%) compared to CEA or KRAS alone [74]. Another study
by Kanda et al. identified GNAS mutations in 64.1% of
the patients in a screening population with IPMN [75].
The same group detected TP53 mutations in the pancreatic
juice in 9.1% of intermediate-grade IPMNs, 17.8% of PanIN-
2 lesions, 38.1% of high-grade IPMNs, 47.6% of PanIN-3
lesions, and 75% of invasive pancreatic adenocarcinomas.
Interestingly, no TP53 mutations were found in PanIN-1
lesions or low-grade IPMNs [76]. Although GNAS, KRAS,
and TP53 mutations are helpful in identifying patients with
IPMN, they occur early in the development of IPMNs and
cannot be used to identify those individuals with high-grade
dysplasia or invasive disease. Das et al. recently published
seminal results regarding the detection of high-risk IPMN
lesions. By analyzing the cyst fluid of IPMNs, they found that
the monoclonal antibody Das-1 has 89% sensitivity and 100%
specificity to detect high-risk/malignant IPMNs [77].
Moreover, recent reports demonstrated a level of hyper-
methylation in IPMN (e.g., p16/CDKN2A, cyclin-dependent
kinase inhibitor 1C (CDKN1C), SRY- (sex determining region
Y-) box 17 (SOX17)). An increasing number of hypermethy-
lated loci are associated with an increasing grade of dysplasia
[78].
3.3. Clinical Relevance of IPMN. In summary, IPMNs are
premalignant cystic lesions usually arising from intestinal
type IPMN, the tubular adenocarcinoma can be detected
and treated before the onset of malignancy. A current
challenge is the differentiation of cystic lesions (serous
cystic neoplasm (SCN), mucinous cystic neoplasm (MCN),
solid pseudopapillary neoplasm (SPN), and pseudocysts) and
especially IPMN preoperatively. These cystic lesions appear
different in clinical and radiologic diagnostic [47]. Table 2
summarizes the core characteristics of the different cystic
pancreatic lesions. In particular, diagnostic classification of
the IPMN subtypes (e.g., by cystic fluid) is important for
individualized patient treatment.
Generally, resection of all MD-IPMNs (and mixed duct-
type IPMN) and of BD-IPMNs with “worrisome features”
is indicated. The recently published revised international
consensus guidelines discuss this topic in detail [50].
Bettermarkers are required to accurately identify patients
who would benefit from surgical resection or could be
placed under surveillance. The examination of pancreatic
juice/cystic fluid seems to be a promising diagnostic option.
Recently, Hara et al. showed that pancreatic juice cytology
with MUC stain is highly reliable for the identification of the
histological subtypes of IPMN [79]. Other authors reported
about the identification of high-risk/malignant lesions by
examination of the cyst fluid of IPMNs either by analyzing
the MUC expression and cyst fluid cytokine levels (e.g.,
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Figure 6: (a) Overview of a multicystic MCN (H&E 2x) with cuboidal to columnar epithelial lining, mild dysplasia, and underlying ovarian
type stroma. (b) High power view of MCN with columnar epithelial lining and underlying ovarian type stroma (H&E 40x).
interleukin-1 beta) or by recognition of atypical cell compo-
nents [80–83].
4. Mucinous Cystic Neoplasm (MCN)
MCNs of the pancreas are the most infrequent precursor
lesions of pancreatic cancer.The accurate prevalence ofMCN
is difficult to assess; a recent publication by Valsangkar et
al. reported about 23% of MCN in patients with resected
cystic tumors of the pancreas [84]. MCNs mainly occur in
women and are typically located in the pancreatic body and
tail [42, 60, 85, 86]. These cystic lesions are almost solitary
and the vast majority of MCNs are asymptomatic and found
incidentally [15]. On imaging, the cysts appear septated and
may contain calcifications. Like IPMNs, MCNs as mucinous
pancreatic lesions have a high CEA and mucinous cytology
in the cyst fluid [87, 88]. In contrast to IPMNs, MCNs usually
present no obvious connection to the main pancreatic duct
and no dilatation of the main pancreatic duct is typically
detectable [12]. The prognosis for patients with noninvasive
MCN is very favorable (five-year survival almost 100%), and
also for patients who undergo resection for an invasive MCN
the five-year survival rate is nearly up to 60% [86].
4.1. Histology and Pathogenesis. MCNs are cystic lesions that
can grow very large. They present with a plain surface and
a fibrous pseudocapsule with variable thickness and often
with calcifications. The presence of mural nodules on the
inside of the capsule correlates with malignancy [15, 89].
Microscopically, the epithelial lining of an MCN consists of
columnar cells with a varying degree of dysplasia (Figure 6).
On the basis of the degree of dysplasia (atypia), noninvasive
MCNs are classified into low-grade dysplasia, moderate dys-
plasia, and high-grade dysplasia. About one-third of MCNs
become invasive, and when they do, they usually form ductal
adenocarcinomas [90].
Furthermore, one of the diagnostic clues of MCNs is the
presence of an ovarian-like stroma underlying the neoplastic
epithelium. The stroma expresses progesterone and estrogen
receptors and can even undergo luteinization akin to the
actual ovarian stroma [12, 89]. The epithelial cells of MCNs
show immunoreactivity for epithelial markers including
EMA, CEA, and cytokeratins 7, 8/18, and 19 and for themucin
markersMUC5AC andMUC2.MUC1 is usually expressed in
high-grade lesions and invasive carcinomas.The ovarian-like
stroma is positive for vimentin and smooth-muscle actin in
addition to the progesterone receptor and estrogen receptor
[15, 89].
4.2. Molecular Pathology. Themolecular changes underlying
MCN formation and progression are not entirely clear.
KRAS mutations have been detected in MCNs with low-
grade dysplasia and with increased frequency in advanced
cases, while mutations of TP53, p16, and SMAD4/DPC4 have
been mainly observed in high-grade dysplasia and invasive
carcinomas [12, 23, 91, 92]. A recent exome sequencing
analysis by Wu et al. showed that MCNs contain an average
of 16 ± 7.6 somatic mutations (cf. with 27 ± 12 for IPMNs)
and are characterized by KRAS, TP53, and RING-type zinc
finger protein 43 (RNF43) mutations [93]. Interestingly, in
this analysis, MCN harbored no mutations of GNAS and
thereforeGNASmay be a usefulmarker for the differentiation
between IPMN and MCN.
4.3. Clinical Relevance of MCN. Although MCNs harbor a
low risk of malignancy (prevalence of invasive carcinoma
about 13%), surgery is indicated for any patient. Because, in
particular, MCNs mainly occur in young patients and are
mostly located in the body and tail of the pancreas, resection
is the most appropriate and reliable treatment [42, 50].
Only frail and elderly patients for whom surgery is a
higher risk should be placed under surveillance [15, 50].
5. Conclusion
There is still a lot to be learned about the biology of the
three different precursor lesions of pancreatic cancer (PanIN,
IPMN, and MCN). Early detection of these lesions would
create an opportunity to prevent patients from developing
invasive pancreatic cancer. However, clinical detection of
these lesions is still challenging, even with modern high-
resolution imaging methods. Currently, PanIN lesions (espe-
cially <5mm) are not detectable using available imaging
methods.Moreover, diagnostic differentiation of the different
cystic pancreatic lesions (i.e., IPMN from MCN or SCN and
SPN) is often complicated.
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From this comes the need for reliable biomarkers to detect
and differentiate precursor lesions for pancreatic cancer.
Analyzing genetic alterations in pancreatic juice/cystic fluid
may be a diagnostic option for the future, as preliminary
studies have already demonstrated. Prospective studies to
validate these markers are needed to put them into clinical
practice.
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